BPC-157 + TB-500 Wolverine Stack Reconstitution & Dosing Calculator

Wolverine Stack - Dosing Protocol

The Wolverine stack combines BPC-157 (local repair via VEGF, nitric oxide, GH receptor pathways) with TB-500 (systemic repair via actin regulation and cell migration). The protocol typically uses a loading phase followed by a maintenance phase.

Loading Phase (Weeks 1-4)

Maintenance Phase (Weeks 5-12)

For the complete protocol breakdown, see the Wolverine stack guide.

Blend Reconstitution - Quick Reference

Common blend ratios: 1:1 (equal mg BPC and TB) or 1:2 (double TB-500). The ratio determines how much TB-500 you receive per BPC-157 dose. Use the calculator above to see the exact per-peptide breakdown for your vial.

Standalone TB-500 Reconstitution

If using separate vials rather than a blend, TB-500 is typically supplied in 5 mg or 10 mg standalone vials.

For standalone BPC-157 reconstitution, see the BPC-157 calculator.

BPC-157 vs TB-500 - Comparison

How Long Does a Wolverine Blend Vial Last?

Vial duration is determined by whichever peptide runs out first (in equal-ratio blends, both run out simultaneously). See how to store peptides.

How to Verify Quality

A quality Wolverine blend should show two distinct HPLC peaks - BPC-157 at MW 1,419.53 Da and TB-500 at approximately 4,963 Da. Mass spec should confirm both weights. Check that the stated peptide quantities match - underdosing is more common in blends than single-peptide vials. Cross-reference with independent lab test results.

Where Every BPC-157 and TB-500 Amount Comes From

Peptigrity does not recommend a dose for either compound; the amounts below are those recorded in the studies named, shown with their evidence level. No published study has tested BPC-157 and TB-500 together, in humans or in animals, and no human dose-ranging study exists for BPC-157 or for TB-500. The only human pharmacokinetic data anywhere in TB-500's class comes from intravenous recombinant thymosin β4 at 0.05–25 µg/kg — a different molecule, a different route, and roughly three orders of magnitude from the milligram figures used subcutaneously.

Two rows deserve reading twice. The intravenous BPC-157 study enrolled two people who had both used BPC-157 previously, observed them for three days, and reported no pharmacokinetic curve. And the widely repeated 5–7 day half-life for TB-500 has no locatable source, which matters because dosing frequency is usually reasoned from a half-life. BPC-157's own half-life is under 30 minutes, with hepatic metabolism and renal clearance.

Running Two Separate Vials - Concentration, Units and Draws

Concentration is peptide mass divided by diluent volume, and this part is deterministic. Neither compound has an approved label, so no regulator specifies a diluent volume for either, and the volume you choose is fixed the moment the water goes in. Two vials at the same concentration make every later conversion easier; two vials at different concentrations make one of them an error waiting to happen. The worked example below puts a 10 mg vial of each in 2 mL.

At that concentration, the volume and units for an amount drawn from either vial are below. These are examples of a calculation, not recommendations about amounts.

A U-100 unit is 0.01 mL by definition, so units equal millilitres multiplied by 100. The resolution problem sits at the small end: the same 10 mg vial in 1 mL gives 10 mg/mL, where 500 mcg is 0.05 mL — 5 units, and in 3 mL gives 3.33 mg/mL, where 500 mcg is 0.15 mL — 15 units. Fix that with diluent volume before mixing rather than with a steadier hand afterwards, and never top up an open vial: every volume calculated before the top-up is then wrong, and nothing on the vial records it.

Two vials at the same concentration also empty at very different rates, because the figures in circulation put one compound in hundreds of micrograms and the other in milligrams. The table below is division — vial mass by amount per draw — and nothing about it is a recommendation.

That ratio determines when each vial runs out, how many stoppers get punctured, and what a reorder actually costs. The physical procedure is identical for both vials: swab the stopper, run the diluent down the glass wall, swirl rather than shake, and write the concentration and the date on each vial. See reconstituting peptides step by step and does shaking damage peptides.

Storage - What No Label Sets

No peer-reviewed stability or storage study of BPC-157 has been published, so every shelf-life figure in circulation for it is vendor-derived. Neither compound has an approved label, which means no regulator has set an in-use period for either vial — any “discard after N days” figure attached to a research vial has been borrowed from a compound that had a label, including the commonly cited 28-day window used in the vial-duration table above. A large amount of BPC-157 storage advice rests on methionine oxidation, and the sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — contains no methionine, cysteine, tryptophan or tyrosine. General handling practice still applies; see how to store peptides.

Blend Vial or Two Vials

A blend saves an injection and costs the verification, and its ratio is fixed by the seller. The table below compares the two arrangements on the points that change the arithmetic and the checks.

Combined with the draws-per-vial arithmetic above — where one component is drawn in hundreds of micrograms and the other in milligrams — a single ratio chosen by a seller is unlikely to match how either compound is actually being used. The two-component volume arithmetic is also handled by the blend calculator.

Rotating Sites With Two Injections

A two-vial arrangement puts twice as many punctures into the same finite set of sites, and the measured consequence of concentrating injections comes from approved labels rather than from stacking research: injection site reactions occurred in 25% of patients on tesamorelin's label, with the trial table recording 17% against 6% on placebo, and bremelanotide's label records 13.2% against 8.4%.

• Choose the two sites before drawing anything. Abdomen and thigh are the sites named on an approved peptide label — bremelanotide's. Upper arm and upper buttock are convention rather than label, and neither is easy to inspect.
• Separate the two compounds by site, not just by time. Two injections into one area concentrates the tissue insult that the reaction rates above are measuring.
• Inspect before each injection. A lump, a bruise or a reactive patch is not a usable site. Skip it and record why.
• Use a fresh needle for every draw and every injection. A needle through a stopper is blunted and no longer sterile, and two vials double how often that decision is made.
• Record which compound went where. With two compounds in rotation, an unrecorded site sequence makes a local reaction unattributable.
• Dispose into a sharps container, without recapping. Recapping is behind most domestic needlestick injuries.

No trial in our fact base has compared rotation schemes for any peptide, so every “return to a site after N weeks” figure in circulation is convention rather than measurement. And no approved peptide label in our fact base specifies a needle gauge for a self-administered research vial, so Peptigrity does not publish one. General technique is in how to inject peptides and disposal in how to dispose of peptide syringes safely. Anything involving your own tissue, symptoms or medication is a clinician's question.